Currently, there are 135.04M common shares owned by the public and among those 120.71M shares have been available to trade.
The company’s stock has a 5-day price change of -18.68% and 26.95% over the past three months. MCRB shares are trading -34.36% year to date (YTD), with the 12-month market performance down to -61.55% lower. It has a 12-month low price of $0.54 and touched a high of $2.46 over the same period. MCRB has an average intraday trading volume of 4.18 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -5.68%, -10.17%, and -7.04% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Seres Therapeutics Inc (NASDAQ: MCRB) shares accounts for 30.16% of the company’s 135.04M shares outstanding.
It has a market capitalization of $140.02M and a beta (3y monthly) value of 2.01. The earnings-per-share (ttm) stands at -$1.18. Price movements for the stock have been influenced by the stock’s volatility, which stands at 16.07% over the week and 14.77% over the month.
Earnings per share for the fiscal year are expected to increase by 11.26%, and 23.40% over the next financial year.
Looking at the support for the MCRB, a number of firms have released research notes about the stock. Oppenheimer stated their Outperform rating for the stock in a research note on June 26, 2023, with the firm’s price target at $12. JP Morgan coverage for the Seres Therapeutics Inc (MCRB) stock in a research note released on April 21, 2023 offered a Neutral rating with a price target of $7. Goldman was of a view on July 23, 2021 that the stock is Sell, while Goldman gave the stock Neutral rating on May 18, 2021, issuing a price target of $24. Chardan Capital Markets on their part issued Buy rating on March 05, 2021.
